Cover Image
市場調查報告書

PharmaPoint:大腸躁鬱症 (IBS) - EU5個國家的醫藥品市場2023年為止的預測與市場分析

PharmaPoint: Irritable Bowel Syndrome - 5EU Drug Forecast and Market Analysis to 2023

出版商 GlobalData 商品編碼 325950
出版日期 內容資訊 英文 139 Pages
訂單完成後即時交付
價格
Back to Top
PharmaPoint:大腸躁鬱症 (IBS) - EU5個國家的醫藥品市場2023年為止的預測與市場分析 PharmaPoint: Irritable Bowel Syndrome - 5EU Drug Forecast and Market Analysis to 2023
出版日期: 2014年12月31日 內容資訊: 英文 139 Pages
簡介

大腸躁鬱症 (IBS)是常見的障礙,關係到腸道機能的變化,特徵是腹部的不適感。IBS雖然不是生死攸關的疾,但會強烈影響患者的生活品質 (QOL) 。

本報告提供EU5個國家大腸躁鬱症 (IBS) 治療藥之市場相關調查分析,提供您疾病概要與指南,競爭情形,主要藥物的詳細資訊 (產品說明,安全性,有效性) 、SWOT分析,銷售額預測,影響分析 (趨勢,推動因素·阻礙因素) 等相關的系統性資訊。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 病因·病理生理學
  • 分類
  • 症狀
  • 預後
  • 生活品質 (QOL)

第4章 疾病的管理

  • 診斷和治療概要
  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 英國

第5章 競爭評估

  • 概要
  • 產品簡介:領導品牌
  • 其他藥效分類

第6章 未滿足需求和機會

  • 概要
  • 更有效的藥物療法
  • IBS D類型的治療方法
  • IBS M類型的治療方法
  • 解決腹痛和飽脹感症狀的治療方法
  • 提高IBS的診斷率

第7章 開發平台評估

  • 概要
  • 臨床開發中的潛力藥物
  • 產品簡介:後期開發平台 (IBS D)
  • 產品簡介:後期開發平台 (IBS C)
  • 其他

第8章 市場預測

  • 全球市場
  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 英國

第9章 附錄

圖表

目錄
Product Code: GDHC271CFR

Irritable Bowel Syndrome (IBS) is a common disorder characterized by abdominal discomfort associated with altered bowel function. Although IBS is not a life-threatening disorder, it has a considerable effect on patients' quality of life (QOL). In terms of volume, the IBS market is a large, albeit naive, one, with only a small number of pharmacotherapies indicated for the treatment of the disorder, and it is also characterized by significant unmet needs.

GlobalData estimated that prescription drug sales for IBS were approximately $4.0m in France in 2013. Ironwood/Actavis/Almirall/Astellas' Linzess is the only available product indicated for IBS-C in Germany, which was launched in 2013. Salix/Alfa Wassermann/Norgine/Bama-Geve's Xifaxan and antidepressants are used off-label for the management of IBS patients in Italy. Salix/Alfa Wassermann/Norgine/Bama-Geve's Xifaxan and antidepressants are used off-label for the management of IBS patients in Spain. Ironwood/Actavis/Almirall/Astellas' Linzess is the only available product indicated for IBS-C in the UK, which was launched in 2013.

Scope

  • Overview of Irritable Bowel Syndrome including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on the key drugs in the 5EU including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for the top drugs in the 5EU from 2013-2023.
  • Analysis of the impact of key events as well the drivers and restraints affecting the 5EU Irritable Bowel Syndrome

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Irritable Bowel Syndrome
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of drug performance
  • Obtain sales forecast for drugs from 2013-2023 in the 5EU

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Classification
  • 3.3. Symptoms
  • 3.4. Prognosis
  • 3.5. Quality of Life

4. Disease Management

  • 4.1. Diagnosis and Treatment Overview
    • 4.1.1. Diagnosis
    • 4.1.2. Treatment Guidelines and Leading Prescribed Drugs
    • 4.1.3. Clinical Practice
  • 4.2. France
  • 4.3. Germany
  • 4.4. Italy
  • 4.5. Spain
  • 4.6. UK

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Product Profiles - Major Brands, IBS-C
    • 5.2.1. Linzess (linaclotide)
  • 5.3. Product Profiles - Major Brands, Other
    • 5.3.1. Antidepressants
  • 5.4. Other Therapeutic Classes

6. Unmet Need and Opportunity

  • 6.1. Overview
  • 6.2. More Effective Pharmacotherapies
    • 6.2.1. Unmet Need
    • 6.2.2. Gap Analysis
    • 6.2.3. Opportunity
  • 6.3. Therapies for the IBS-D Subtype
    • 6.3.1. Unmet Need
    • 6.3.2. Gap Analysis
    • 6.3.3. Opportunity
  • 6.4. Therapies for the IBS-M Subtype
    • 6.4.1. Unmet Need
    • 6.4.2. Gap Analysis
    • 6.4.3. Opportunity
  • 6.5. Therapies to Address Abdominal Pain and Bloating Symptoms
    • 6.5.1. Unmet Need
    • 6.5.2. Gap Analysis
    • 6.5.3. Opportunity
  • 6.6. Improved Diagnosis Rate for IBS
    • 6.6.1. Unmet Need
    • 6.6.2. Gap Analysis
    • 6.6.3. Opportunity

7. Pipeline Assessment

  • 7.1. Overview
  • 7.2. Promising Drugs in Clinical Development
  • 7.3. Product Profiles - Late-Stage Pipeline, IBS-D
    • 7.3.1. Eluxadoline
    • 7.3.2. Ibodutant (MEN-15596)
    • 7.3.3. Xifaxan (rifaximin)
  • 7.4. Product Profiles - Late-Stage Pipeline, IBS-C
    • 7.4.1. Plecanatide
    • 7.4.2. Tenapanor (AZD1722, RDX5791)
  • 7.5. Other Drugs in Development for IBS

8. Market Outlook

  • 8.1. Global Markets
    • 8.1.1. Drivers and Barriers - Global Issues
  • 8.2. France
    • 8.2.1. Forecast
    • 8.2.2. Key Events
    • 8.2.3. Drivers and Barriers
  • 8.3. Germany
    • 8.3.1. Forecast
    • 8.3.2. Key Events
    • 8.3.3. Drivers and Barriers
  • 8.4. Italy
    • 8.4.1. Forecast
    • 8.4.2. Key Events
    • 8.4.3. Drivers and Barriers
  • 8.5. Spain
    • 8.5.1. Forecast
    • 8.5.2. Key Events
    • 8.5.3. Drivers and Barriers
  • 8.6. UK
    • 8.6.1. Forecast
    • 8.6.2. Key Events
    • 8.6.3. Drivers and Barriers

9. Appendix

  • 9.1. Bibliography
  • 9.2. Abbreviations
  • 9.3. Methodology
  • 9.4. Forecasting Methodology
    • 9.4.1. Diagnosed IBS Patients
    • 9.4.2. Drugs Included in Each Therapy Type
    • 9.4.3. Launch and Patent Expiry Dates
    • 9.4.4. General Pricing Assumptions
    • 9.4.5. Individual Drug Assumptions
    • 9.4.6. Generic Erosion
    • 9.4.7. Pricing of Pipeline Agents
  • 9.5. Primary Research - KOLs Interviewed for This Report
  • 9.6. Primary Research - Prescriber Survey
  • 9.7. About the Authors
    • 9.7.1. Analyst
    • 9.7.2. Therapy Area Director
    • 9.7.3. Global Head of Healthcare
  • 9.8. About GlobalData
  • 9.9. Disclaimer

List of Tables

  • Table 1: Common Symptoms of IBS
  • Table 2: Summary of the Various Diagnostic Criteria Used for the Diagnosis of IBS
  • Table 3: Treatment Guidelines for IBS
  • Table 4: Leading Prescribed Drugs for IBS by Predominant Symptoms in the 5EU, 2014†
  • Table 5: IBS Diagnosis and Treatment, Country Profile - France
  • Table 6: IBS Diagnosis and Treatment, Country Profile - Germany
  • Table 7: IBS Diagnosis and Treatment, Country Profile - Italy
  • Table 8: IBS Diagnosis and Treatment, Country Profile - Spain
  • Table 9: IBS Diagnosis and Treatment, Country Profile - UK
  • Table 10: Leading Branded Treatments for IBS, 2014
  • Table 11: Product Profile - Linzess
  • Table 12: Efficacy Responder Rates in Linzess' Two Placebo-Controlled IBS-C Trials: At Least Nine Out of 12 Weeks
  • Table 13: Efficacy Responder Rates in Linzess' Two Placebo-Controlled IBS-C Trials: At Least Six Out of 12 Weeks
  • Table 14: Safety of Linzess - Most Frequently Reported Adverse Events
  • Table 15: Linzess SWOT Analysis, 2014
  • Table 16: Use of Antidepressants in IBS, SWOT Analysis, 2014
  • Table 17: Summary of Other Therapeutic Classes of Pharmacologics in IBS, 2014
  • Table 18: Unmet Needs and Opportunities in IBS
  • Table 19: Drugs in Late-Stage Clinical Development for IBS, 2014
  • Table 20: Product Profile - Eluxadoline
  • Table 21: Eluxadoline SWOT Analysis, 2014
  • Table 22: Product Profile - Ibodutant
  • Table 23: Ibodutant SWOT Analysis, 2014
  • Table 24: Product Profile - Xifaxan
  • Table 25: Safety of Xifaxan - Most Frequently Reported Adverse Events
  • Table 26: Xifaxan SWOT Analysis, 2014
  • Table 27: Product Profile - Plecanatide
  • Table 28: Plecanatide SWOT Analysis, 2014
  • Table 29: Product Profile - Tenapanor
  • Table 30: Tenapanor SWOT Analysis, 2014
  • Table 31: Drugs in Early-Stage Clinical Development for IBS, 2014
  • Table 32: Global IBS Market - Drivers and Barriers, 2013-2023
  • Table 33: Sales Forecasts ($m) for IBS in France, 2013-2023
  • Table 34: Key Events Impacting Sales for IBS in France, 2013-2023
  • Table 35: IBS Market in France - Drivers and Barriers, 2013-2023
  • Table 36: Sales Forecasts ($m) for IBS in Germany, 2013-2023
  • Table 37: Key Events Impacting Sales for IBS in Germany, 2013-2023
  • Table 38: IBS Market in Germany - Drivers and Barriers, 2013-2023
  • Table 39: Sales Forecasts ($m) for IBS in Italy, 2013-2023
  • Table 40: Key Events Impacting Sales for IBS in Italy, 2013-2023
  • Table 41: IBS Market in Italy - Drivers and Barriers, 2013-2023
  • Table 42: Sales Forecasts ($m) for IBS in Spain, 2013-2023
  • Table 43: Key Events Impacting Sales for IBS in Spain, 2013-2023
  • Table 44: IBS Market in Spain - Drivers and Barriers, 2013-2023
  • Table 45: Sales Forecasts ($m) for IBS in the UK, 2013-2023
  • Table 46: Key Events Impacting Sales for IBS in the UK, 2013-2023
  • Table 47: IBS Market in the UK - Drivers and Barriers, 2013-2023
  • Table 48: Key Launch Dates
  • Table 49: Key Patent Expiries
  • Table 50: High-Prescribing Physicians (Non-KOLs) Surveyed, by Country

List of Figures

  • Figure 1: Summary of Pharmacotherapies Used to Treat IBS
  • Figure 2: IBS - Phase IIb-III Pipeline, October 2014
  • Figure 3: Competitive Assessment of Late-Stage Pipeline Agents in IBS, 2013-2023
  • Figure 4: Clinical and Commercial Positioning of Eluxadoline
  • Figure 5: Clinical and Commercial Positioning of Ibodutant
  • Figure 6: Clinical and Commercial Positioning of Xifaxan
  • Figure 7: Clinical and Commercial Positioning of Plecanatide
  • Figure 8: Clinical and Commercial Positioning of Tenapanor
  • Figure 9: Sales for IBS in France by Therapy Type, 2013-2023
  • Figure 10: Sales for IBS in Germany by Therapy Type, 2013-2023
  • Figure 11: Sales for IBS in Italy by Therapy Type, 2013-2023
  • Figure 12: Sales for IBS in Spain by Therapy Type, 2013-2023
  • Figure 13: Sales for IBS in the UK by Therapy Type, 2013-2023
Back to Top